Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Mats Wahlstrom is Director at Trisalus Life Sciences. OQRO lists 11 transactions filed with the SEC under this name, the latest on Nov 16, 2026, each linked to the official Form 4.
Director
Disclosures on record
11
Companies involved
2
3 buys, median +35.4 pts vs S&P 500, beat it 3 of 3 times.
Average +41.9 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Nov 23, 2024 to May 18, 2026, measured from the first close after the filing. Past results, not a forecast.
3 purchases disclosed; 100% of the 3 measured at 90 days finished ahead of the index. $1,000 placed after each of the 1 purchases disclosed since 2025-11-16 would be worth $771 today ($1K put in); the same in the S&P 500 (SPY): $1K.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
Trisalus Life SciencesTLSI
8 disclosures · Nov 2024 – Nov 2026 · 5 bought
Nov 12, 2026Bought~$112Kdisclosed Nov 16
DetailsOfficial recordMay 15, 2026Bought~$152Kdisclosed May 18
Equal weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
May 14, 202638Kdisclosed May 15
DetailsOfficial recordMay 14, 202634Kdisclosed May 15
DetailsOfficial recordMay 14, 202675Kdisclosed May 15
DetailsOfficial recordNov 22, 2024Bought~$23Kdisclosed Nov 25
DetailsOfficial recordNov 21, 2024Bought~$39Kdisclosed Nov 23
DetailsOfficial recordNov 20, 2024Bought~$8.5Kdisclosed Nov 23
DetailsOfficial recordCoherus OncologyCHRS
3 disclosures · May 2025 – Jun 2026 · 1 sold
Jun 5, 202630Kdisclosed Jun 9
DetailsOfficial recordJun 5, 202660Kdisclosed Jun 9
DetailsOfficial recordMay 23, 2025Sold~$74Kdisclosed May 28
DetailsOfficial recordAs of the latest filing on , Mats Wahlstrom reported holding 197,555 shares of Trisalus Life Sciences (TLSI), worth about $448K at the last close of $2 (Nov 16, 2026). Holdings are also on file at Coherus Oncology (CHRS); together they are worth about $464K. In the last 12 months, Mats Wahlstrom bought $264K in 2 open-market purchases.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Trisalus Life Sciences TLSI | 197,555 | 198K direct | $2 | $448K | Nov 12, 2026 |
| Coherus Oncology CHRS | 30,000 | 30K direct | $1 | $15K | Jun 5, 2026 |
Is this Mats Wahlstrom’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Mats Wahlstrom bought shares on the open market in 2024 and 2026 across 2 companies. Sales in 4 of the 12 years since 2015.
Mats Wahlstrom reported 5 open-market purchases and 10 sales since 2015; purchases in 2 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $264K2×2 trades | — |
| 2025 | — | $74K1×1 trade |
| 2024 | $70K3×3 trades | — |
| 2020 | — | $5.81M3×3 trades |
| 2016 | — | $1.47M2×2 trades |
| 2015 | — | $4.69M4×4 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Nov 12, 2026, Mats Wahlstrom reported holding 197,555 shares of Trisalus Life Sciences (TLSI). At the last close of $2 on Nov 16, 2026, that is about $448K. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Mats Wahlstrom reported 2 open-market purchases worth $264K, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Mats Wahlstrom bought shares on the open market in 2024 and 2026 across 2 companies. Sales in 4 of the 12 years since 2015.
In SEC filings since 2015: the latest open-market purchase is from 2026; the latest open-market sale is from 2025.
2 companies: Trisalus Life Sciences (TLSI, 2024–2026), Coherus Oncology (CHRS, 2015–2025).
Mats Wahlstrom reported 0 open-market purchases and 10 sales here, 2015 to 2025.
Mats Wahlstrom reported 5 open-market purchases and 0 sales here, 2024 to 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.